Cargando…

In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis

[Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delive...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Nazia, Farooq, Uzma, Das, Ayan Kumar, Sharma, Kalicharan, Mirza, Mohd. Aamir, Fatima, Suhail, Singh, Omana, Ansari, Mohammad Javed, Ali, Asgar, Iqbal, Zeenat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947946/
https://www.ncbi.nlm.nih.gov/pubmed/36844532
http://dx.doi.org/10.1021/acsomega.2c07718
_version_ 1784892671672713216
author Hassan, Nazia
Farooq, Uzma
Das, Ayan Kumar
Sharma, Kalicharan
Mirza, Mohd. Aamir
Fatima, Suhail
Singh, Omana
Ansari, Mohammad Javed
Ali, Asgar
Iqbal, Zeenat
author_facet Hassan, Nazia
Farooq, Uzma
Das, Ayan Kumar
Sharma, Kalicharan
Mirza, Mohd. Aamir
Fatima, Suhail
Singh, Omana
Ansari, Mohammad Javed
Ali, Asgar
Iqbal, Zeenat
author_sort Hassan, Nazia
collection PubMed
description [Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delivery system. The proposed work fabricates a luliconazole-loaded nanostructured lipid carrier-based transvaginal gel for combating Candida albicans biofilm and disease amelioration. The interaction and binding affinity of luliconazole against the proteins of C. albicans and biofilm were assessed using in silico tools. A systematic QbD analysis was followed to prepare the proposed nanogel using a modified melt emulsification–ultrasonication–gelling method. The DoE optimization was logically implemented to ascertain the effect of independent process variables (excipients concentration; sonication time) on dependent formulation responses (particle size; polydispersity index; entrapment efficiency). The optimized formulation was characterized for final product suitability. The surface morphology and dimensions were spherical and ≤300 nm, respectively. The flow behavior of an optimized nanogel (semisolid) was non-Newtonian similar to marketed preparation. The texture pattern of a nanogel was firm, consistent, and cohesive. The release kinetic model followed was Higuchi (nanogel) with a % cumulative drug release of 83.97 ± 0.69% in 48 h. The % cumulative drug permeated across a goat vaginal membrane was found to be 53.148 ± 0.62% in 8 h. The skin-safety profile was examined using a vaginal irritation model (in vivo) and histological assessments. The drug and proposed formulation(s) were checked against the pathogenic strains of C. albicans (vaginal clinical isolates) and in vitro established biofilms. The visualization of biofilms was done under a fluorescence microscope revealing mature, inhibited, and eradicated biofilm structures.
format Online
Article
Text
id pubmed-9947946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-99479462023-02-24 In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis Hassan, Nazia Farooq, Uzma Das, Ayan Kumar Sharma, Kalicharan Mirza, Mohd. Aamir Fatima, Suhail Singh, Omana Ansari, Mohammad Javed Ali, Asgar Iqbal, Zeenat ACS Omega [Image: see text] Candidal vulvovaginitis involving multispecies of Candida and epithelium-bound biofilm poses a drug-resistant pharmacotherapeutic challenge. The present study aims for a disease-specific predominant causative organism resolution for the development of a tailored vaginal drug delivery system. The proposed work fabricates a luliconazole-loaded nanostructured lipid carrier-based transvaginal gel for combating Candida albicans biofilm and disease amelioration. The interaction and binding affinity of luliconazole against the proteins of C. albicans and biofilm were assessed using in silico tools. A systematic QbD analysis was followed to prepare the proposed nanogel using a modified melt emulsification–ultrasonication–gelling method. The DoE optimization was logically implemented to ascertain the effect of independent process variables (excipients concentration; sonication time) on dependent formulation responses (particle size; polydispersity index; entrapment efficiency). The optimized formulation was characterized for final product suitability. The surface morphology and dimensions were spherical and ≤300 nm, respectively. The flow behavior of an optimized nanogel (semisolid) was non-Newtonian similar to marketed preparation. The texture pattern of a nanogel was firm, consistent, and cohesive. The release kinetic model followed was Higuchi (nanogel) with a % cumulative drug release of 83.97 ± 0.69% in 48 h. The % cumulative drug permeated across a goat vaginal membrane was found to be 53.148 ± 0.62% in 8 h. The skin-safety profile was examined using a vaginal irritation model (in vivo) and histological assessments. The drug and proposed formulation(s) were checked against the pathogenic strains of C. albicans (vaginal clinical isolates) and in vitro established biofilms. The visualization of biofilms was done under a fluorescence microscope revealing mature, inhibited, and eradicated biofilm structures. American Chemical Society 2023-02-10 /pmc/articles/PMC9947946/ /pubmed/36844532 http://dx.doi.org/10.1021/acsomega.2c07718 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Hassan, Nazia
Farooq, Uzma
Das, Ayan Kumar
Sharma, Kalicharan
Mirza, Mohd. Aamir
Fatima, Suhail
Singh, Omana
Ansari, Mohammad Javed
Ali, Asgar
Iqbal, Zeenat
In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title_full In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title_fullStr In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title_full_unstemmed In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title_short In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis
title_sort in silico guided nanoformulation strategy for circumvention of candida albicans biofilm for effective therapy of candidal vulvovaginitis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947946/
https://www.ncbi.nlm.nih.gov/pubmed/36844532
http://dx.doi.org/10.1021/acsomega.2c07718
work_keys_str_mv AT hassannazia insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT farooquzma insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT dasayankumar insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT sharmakalicharan insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT mirzamohdaamir insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT fatimasuhail insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT singhomana insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT ansarimohammadjaved insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT aliasgar insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis
AT iqbalzeenat insilicoguidednanoformulationstrategyforcircumventionofcandidaalbicansbiofilmforeffectivetherapyofcandidalvulvovaginitis